BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 990 filers reported holding BAXTER INTL INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $86,606,733 | -50.6% | 2,294,826 | -40.4% | 0.10% | -48.2% |
Q2 2023 | $175,332,148 | +4.2% | 3,848,379 | -7.3% | 0.20% | +2.1% |
Q1 2023 | $168,327,772 | +171.9% | 4,150,093 | +241.7% | 0.19% | +160.8% |
Q4 2022 | $61,896,796 | -8.7% | 1,214,377 | -3.6% | 0.07% | -14.9% |
Q3 2022 | $67,822,000 | -48.0% | 1,259,236 | -38.0% | 0.09% | -43.9% |
Q2 2022 | $130,406,000 | -14.7% | 2,030,307 | +3.0% | 0.16% | -1.3% |
Q1 2022 | $152,851,000 | +2.9% | 1,971,251 | +13.9% | 0.16% | +3.3% |
Q4 2021 | $148,608,000 | +29.9% | 1,731,222 | +21.7% | 0.15% | +19.7% |
Q3 2021 | $114,420,000 | +1.8% | 1,422,598 | +1.8% | 0.13% | +5.0% |
Q2 2021 | $112,450,000 | -17.3% | 1,396,892 | -13.3% | 0.12% | -21.9% |
Q1 2021 | $135,962,000 | -47.4% | 1,612,062 | -49.9% | 0.16% | -51.3% |
Q4 2020 | $258,364,000 | +88.1% | 3,219,884 | +88.6% | 0.32% | +87.1% |
Q3 2020 | $137,329,000 | -0.6% | 1,707,636 | +6.4% | 0.17% | -8.6% |
Q2 2020 | $138,160,000 | -24.8% | 1,604,654 | -29.1% | 0.19% | -38.4% |
Q1 2020 | $183,827,000 | +8.1% | 2,264,161 | +11.3% | 0.30% | +28.0% |
Q4 2019 | $170,038,000 | +13.4% | 2,033,460 | +18.7% | 0.24% | +4.0% |
Q3 2019 | $149,886,000 | +8.9% | 1,713,569 | +2.0% | 0.23% | +9.7% |
Q2 2019 | $137,648,000 | -17.7% | 1,680,672 | -18.3% | 0.21% | -21.0% |
Q1 2019 | $167,248,000 | +103.2% | 2,056,928 | +64.5% | 0.26% | +79.5% |
Q4 2018 | $82,313,000 | +57.5% | 1,250,560 | +84.4% | 0.15% | +89.6% |
Q3 2018 | $52,268,000 | +4.4% | 678,014 | +0.0% | 0.08% | +2.7% |
Q2 2018 | $50,063,000 | +505.9% | 677,988 | +396.7% | 0.08% | +212.5% |
Q2 2017 | $8,263,000 | -35.2% | 136,487 | -44.5% | 0.02% | -33.3% |
Q1 2017 | $12,747,000 | -43.5% | 245,790 | -51.7% | 0.04% | -45.5% |
Q4 2016 | $22,550,000 | -1.9% | 508,562 | +5.3% | 0.07% | -4.3% |
Q3 2016 | $22,989,000 | +21.4% | 482,951 | +87.0% | 0.07% | +6.2% |
Q4 2014 | $18,929,000 | +24.4% | 258,284 | +21.8% | 0.06% | +12.1% |
Q3 2014 | $15,215,000 | -14.1% | 212,000 | -13.5% | 0.06% | -12.1% |
Q2 2014 | $17,714,000 | +33.8% | 245,000 | +36.1% | 0.07% | +37.5% |
Q1 2014 | $13,244,000 | -5.4% | 180,000 | -10.6% | 0.05% | -14.3% |
Q4 2013 | $14,000,000 | -46.7% | 201,300 | -49.7% | 0.06% | -55.6% |
Q3 2013 | $26,269,000 | -5.2% | 399,900 | 0.0% | 0.13% | -19.7% |
Q2 2013 | $27,701,000 | – | 399,900 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |